Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real‐life outcomes of daratumumab treatment-Reference-Cited by-同舟云学术

Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real‐life outcomes of daratumumab treatment

Published:2020-05-29 Issue:2 Volume:105 Page:196-202
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Afram Garbriel¹^ORCID,Gran Charlotte¹^ORCID,Borg Bruchfeld Johanna¹^ORCID,Wagner Arnika Kathleen¹^ORCID,Hussain Alamdar¹,Alici Evren¹,Nahi Hareth¹

Affiliation:

1. Karolinska Institutet Department of Medicine Huddinge Stockholm Sweden

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13426

Reference14 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies

2. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis

3. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

4. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

5. MadduriD.Results from CARTITUDE‐a: A Phase 1b/2 Study of JNJ‐4528 a CAR‐T Cell Therapy Directed Against B‐Cell Maturation Antigen (BCMA) in Patients with Relapse and/or Refractory Multiple Myeloma (R/R MM). 61st American Society of Hematology annual meeting and exposition.2019;Oral abstract #577.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients;Targeted Oncology;2023-09

2. Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial;Advances in Therapy;2023-08-19

3. Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide;Cytotherapy;2023-07

4. The combination of serum calcium levels, neutrophil‑to‑lymphocyte ratio and platelet count in the prognosis of multiple myeloma: A retrospective cohort study and review of the literature;World Academy of Sciences Journal;2022-07-14

5. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies;Biomarker Research;2022-01-09